DCIS Clinical Trial
Official title:
Evaluation of the Ductal Carcinoma In Situ Score for Decisions on Radiotherapy in Patients With Low/Intermediate Risk DCIS
To evaluate whether the use of the Oncotype DX DCIS score can guide delivery of radiation in women with low to moderate risk DCIS who have had breast conserving surgery
A prospective cohort study, conducted in Canada, to evaluate whether the use of the DCIS
score changes the treatment recommended and the treatment received in women with low to
moderate risk DCIS following breast conserving surgery who are candidates for radiation
therapy. We plan to study 280 eligible, consenting women who will have their tumour tissue
specimen sent to Genomic Health to assess their DCIS score.
At each centre, all patients with DCIS referred to radiation oncology will be documented.
When a physician identifies an eligible patient, the patient will be approached by the
referring physician or delegate to voluntarily provide informed consent to participate in
this study. Consenting patients will be registered through the Ontario Clinical Oncology
Group's (OCOG) web-based registration system. Data related to the patient demographics,
surgery details, and tumour characteristics will be collected. The preliminary treatment
recommendation and patient preference for treatment will be documented. Patient Decisional
Conflict will be documented by the patient using the Decisional Conflict Scale (DCS). The
patient's tumour specimen will be sent for analysis to Genomic Health. DCIS score results
will be sent to the referring physician. OCOG will also receive the DCIS score results. The
final treatment recommendation, patient preference, and treatment received by the patient
will be documented. Patient decisional conflict will be documented by the patient using the
DCS. The study data will be verified by source documentation.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00256217 -
Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
|
Phase 2 | |
Completed |
NCT03931928 -
Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients
|
Phase 2 | |
Terminated |
NCT03535506 -
Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery
|
Phase 2 | |
Recruiting |
NCT04797299 -
Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS)
|
||
Completed |
NCT02637024 -
Trial of Radiation Fractionation Schedules for Once-a-Day Accelerated Partial Breast Irradiation
|
Phase 2 | |
Completed |
NCT00148655 -
Educational Interventions for Patients With DCIS
|
N/A | |
Suspended |
NCT03936478 -
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
|
Phase 2 | |
Recruiting |
NCT03878342 -
Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast
|
N/A | |
Recruiting |
NCT03793829 -
Neoadjuvant Multi-epitope HER2 Peptide Vaccine in Patients With HER2-expressing DCIS
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04245150 -
Assessing the Impact of the Microbiome on Breast Cancer Radiotherapy Toxicity
|
||
Recruiting |
NCT06388304 -
THRIVE Study: Positive Affect Training for Endocrine Therapy Medication Adherence
|
N/A | |
Not yet recruiting |
NCT06217458 -
The Added Value of Contrast Enhanced Mammography to Standard Mammography in Assessing the Extent of DCIS
|
N/A | |
Recruiting |
NCT04722692 -
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
|
Phase 3 | |
Enrolling by invitation |
NCT05868252 -
Molecular Analysis of the Sloane Project
|
||
Recruiting |
NCT05912569 -
Delayed Selective Sentinel Node Biopsy for Patients Undergoing Mastectomy for DCIS
|
N/A | |
Recruiting |
NCT04049214 -
Perioperative Mindfulness Proposal
|
N/A | |
Completed |
NCT02061332 -
DC Vaccine for Patients With Ductal Carcinoma In Situ
|
Phase 1/Phase 2 | |
Recruiting |
NCT04916808 -
The AUS-PREDICT Registry for DCIS Patients With DCISionRT Testing
|
||
Withdrawn |
NCT05436808 -
Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer
|
Early Phase 1 | |
Recruiting |
NCT05900986 -
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
|
Phase 1/Phase 2 |